Evaluation of endo- and exo-aryl-substitutions and central scaffold modifications on diphenyl substituted alkanes as 5-lipoxygenase activating protein inhibitors

https://doi.org/10.1016/j.bmcl.2012.04.064Get rights and content

Abstract

A search for a suitable replacement for the central norbornyl scaffold presented in the recently disclosed novel FLAP inhibitors is herein described, as well as the SAR study performed on the endo and exo-aryl groups.

Graphical abstract

The investigation of endo and exo-aryl substitutions and the discovery of the tert-butyl group as a central scaffold on the novel class of FLAP inhibitors are reported.

  1. Download : Download full-size image

References and notes (9)

  • R.W. Friesen et al.

    Ann. Rep. Med. Chem.

    (2005)
    C.D. Funk

    Nat. Rev. Drug Disc.

    (2005)
  • S. Charleson et al.

    Mol. Pharmacol.

    (1992)
  • D.K. Miller et al.

    Nature

    (1990)
  • A. Helgadottir

    Nat. Genet.

    (2004)
There are more references available in the full text version of this article.

Cited by (19)

  • Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis

    2018, European Journal of Medicinal Chemistry
    Citation Excerpt :

    In the second part of the work, Merck group focused on the modulation of 5-quinolinemethoxy-2-methyl ester 25 to improve the metabolic stability of these class of compounds, which occured as a result of the sensitivity of the central norbornane ring toward metabolic oxidation. Therefore, they systematically investigated the optimal ring/alkyl replacements of the central norbornane, and also explored the bioisosteric equivalents of ester functionality with various amide and heterocyclic substituents at 2 position of the exo-aryl ring [64]. After an extensive SAR study, they determined that mono-alkyl replacements of norbornane core such as t-butyl along with an oxadiazolone ring in place of the ester function (27) were pharmacologically beneficial resulting in improved FLAP binding (IC50 = 1.9 nM) and HWB potency (IC50 = 534 nM) as well as an acceptable PK profile (F = 27%) in the series (Fig. 7) [64].

  • Recent advances for FLAP inhibitors

    2015, Bioorganic and Medicinal Chemistry Letters
  • Synthesis of aromatic ketones by Suzuki-Miyaura cross-coupling of acyl chlorides with boronic acids mediated by palladium catalysts deposited over donor-functionalized silica gel

    2015, Catalysis Today
    Citation Excerpt :

    13C{1H} NMR (100.58 MHz, CDCl3, 25 °C): δ 115.7 (CN); 118.0, 128.6, 130.1, 130.2, 132.2, 133.3, 136.3 and 141.3 (aromatics); 195.0 (CO). trans-Chalcone (6m) [25]. 1H NMR (399.95 MHz, CDCl3, 25 °C): δ 7.37–7.43 (m, 3 H), 7.45–7.59 (m, 4 H) and 7.59–7.63 (m, 2 H) (aromatics); 7.80 (d, 1 H, 2JHH = 15.7 Hz, CH), 7.99–8.03 (m, 2 H, aromatics).

View all citing articles on Scopus

Current department: DPS Strategic Operations.

Current department: Global Scientific and Medical Publications.

View full text